Loading
Life sciences · Journal article
Biomedicines · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lung cancer remains the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC), with L858R point mutation or exon 19 deletions accounting for the majority of EGFR mutations. The development of EGFR-targeted therapies has significantly improved clinical outcomes and overall survival in patients harboring these classical activating mutations. However, EGFR exon 20 insertion mutations (Ex20ins) exhibit resistance to earlier-generation tyrosine kinase inhibitors (TKIs), including erlotinib, gefitinib, and afatinib, due to structural alterations that limit drug binding and reduce therapeutic efficacy. To address these challenges, novel EGFR-targeted TKIs and bispecific monoclonal antibodies have emerged as promising treatment strategies for patients with Ex20ins-mutated NSCLC. This review summarizes recent advances in targeted therapies for EGFR Ex20ins, highlighting treatments approved by the US Food and Drug Administration (FDA), including amivantamab and sunvozertinib, as well as emerging agents such as firmonertinib, zipalertinib, and becotarug.